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Abstract
Background: Limited data are available for advanced colorectal neoplasm in asymptomatic individuals aged 40–49
years. We aimed to identify risk factors and develop a simple prediction model for advanced colorectal neoplasm in
these persons.
Methods: Clinical data were collected on 2781 asymptomatic subjects aged 40–49 years who underwent colonoscopy
for routine health examination. Subjects were randomly allocated to a development or validation set. Logistic
regression analysis was used to determine predictors of advanced colorectal neoplasm.
Results: The prevalence of overall and advanced colorectal neoplasm was 20.2 and 2.5% respectively. Older age (45–
49 years), male sex, positive serology of Helicobacter pylori, and high triglyceride and low high-density lipoprotein (HDL)
levels were independently associated with an increased risk of advanced colorectal neoplasm. BMI (body mass index)
was not significant in multivariable analysis. We developed a simple scoring model for advanced colorectal neoplasm
(range 0–9). A cutoff of ≥4 defined 43% of subjects as high risk for advanced colorectal neoplasm (sensitivity, 79%;
specificity, 58%; area under the receiver operating curve = 0.72) in the validation datasets.
Conclusion: Older age (45–49 years), male sex, positive serology of H. pylori, high triglyceride level, and low HDL level
were identified as independent risk factors for advanced colorectal neoplasm.
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Background
Colorectal cancer (CRC) is one of the most prevalent
cancers with a high incidence in Western countries [1].
The incidence of CRC has increased approximately 2–4
times in the past decades in many Asian countries [2, 3].
Because most CRC develops through the adenoma–car-
cinoma sequence [4], CRC can be prevented by colonos-
copy with polypectomy of premalignant lesions. With
respect to the screening age of CRC, since there is a
significant increase in the incidence of CRC during the
sixth decade of life, most CRC guidelines recommend
that screening colonoscopy begin at age 50 for asymp-
tomatic, average-risk individuals [5–7].
Although the frequency of colon cancer over 50 years
has decreased in Western countries, the incidence of
CRC has increased in 12 per 100,000 in 1987 to 18 per
100,000 in 2006, which is a 50% increase over 20 years
among persons aged 40–44 years [8]. Persons younger
than 50 years of age account for 7–9% of those diag-
nosed with CRC, and they tend to present with more
advanced disease and have a less favorable prognosis
than those older than 50 [9]. These clinical characteristics
of younger persons with CRC may be associated with a
time delay in diagnosis; hence, current CRC screening
guidelines exclude the younger population. To minimize
the amount of younger CRC patients who are not cap-
tured by the screening program, a tailored approach based
on the risk of advanced adenoma that considers cost-
effectiveness may be needed because the prevalence of
colonic neoplasm in this age group is significantly lower
than that in those aged ≥50 years [10, 11].
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Regarding advanced adenoma, which is the most reli-
able target lesion for CRC screening, several markers,
including the westernization of lifestyles, obesity, and
metabolic syndrome, have been reported as risk factors
for this neoplasm in the younger population, especially
in those aged 40–49 years. Although these risk factors
can be tailored in CRC screening for the younger age
group, the systematic application of scattered risk factors
may be limited in daily clinical practice. Therefore, the
aim of this study was to identify risk factors and develop
a simple prediction model for advanced colorectal neo-
plasm in asymptomatic individuals aged 40–49 years.
Methods
This study was conducted in two steps. First, we identi-
fied risk factors associated with the occurrence of ad-
vanced colorectal neoplasm in the development set, and
developed a simple scoring model for the prediction of
advanced colorectal neoplasm based on independent risk
factors. Subsequently, we evaluated the clinical effective-
ness of a prediction model for advanced neoplasm in the
validation set. This study was approved by the institu-
tional review board of Gangnam Severance Hospital.
Study population
A cross-sectional study was conducted with 2781
asymptomatic adults aged 40–49 years who underwent
screening colonoscopy for the first time from January
2008 to January 2012 at the Health Promotion Center of
the Gangnam Severance Hospital in Seoul, South Korea.
We excluded the following criteria: 1) previous colorec-
tal examinations, including colonoscopy, sigmoidoscopy,
or barium enema; 2) colonoscopies that had inadequate
bowel preparation and did not reach the cecum; 3) indi-
viduals who had a personal history of colorectal neo-
plasm and inflammatory bowel disease; 4) a history of
colorectal surgery, and 5) any symptoms, weight loss,
anemia, or bleeding. Subjects were randomly allocated
to a development or validation set in a 2:1 ratio.
Colonoscopy
Bowel preparation was performed using 4 L of polyethyl-
ene glycol solution, and subjects underwent a 3-day diet-
ary restriction. The quality of bowel preparation was
determined by the physician who used the following de-
scriptors: excellent, good, fair/adequate, inadequate, and
poor. Those that were inadequate and poor were labeled
as poor preparation and were not included in the final
analysis. Colonoscopies were performed by four endos-
copists who had performed a minimum of 1000 colon-
oscopies, and all endoscopists were gastroenterology
fellowship-trained and board-certified in their respect-
ive field. All examinations were performed using a
standard video colonoscope (CF-H260AI; Olympus,
Tokyo, Japan). All detected polyps were biopsied or re-
moved. All polyp characteristics such as the size, num-
ber, shape, and location were documented. Polyp size
was grossly estimated using open-biopsy forceps
(Olympus FB-28U-1; Aomori Olympus Co., Ltd.,
Aomori, Japan). The polyp shape was classified as
sessile (Is), semipedunculated (Isp), or pedunculated
(Ip) type [12].
Data collection
Subjects’ information, including demographics, labora-
tory tests, colonoscopic findings, and pathology reports,
by review of electronic medical records was collected.
Age was categorized into two groups: 40–44 years and
45–49 years. Body mass index (BMI) was categorized by
the Western Pacific Regional Office of the World Health
Organization criteria: normal (<23 kg/m2), overweight
(23–24.9 kg/m2), or obese (≥25 kg/m2) [13]. According
to the American Joint Committee’s (Joint National
Committee) seventh report, blood pressure was classified
as normal (<120/80 mmHg), prehypertension (120–139/
80–89 mmHg), or hypertension (≥140–90 mmHg or tak-
ing antihypertensive drugs). Laboratory tests included
immunoglobulin G specific for Helicobacter pylori,
which was screened by an enzyme-linked fluorescence
assay in each serum (ELFA, enzyme-linked via Vidas;
bioMerieux Vitek, Inc., USA); elevated total cholesterol
(≥240 mg/dL); elevated triglycerides (≥200 mg/dL);
elevated low-density cholesterol (≥100 mg/dL); and low
high-density lipoprotein cholesterol (HDL-c, <40 mg/
dL). All lipid and lipoprotein levels were measured using
a Hitachi 7600 Modular Dp-110 auto-analyzer, which in-
cluded enzymatic colorimetric tests. Based on the nor-
mal reference range, serum lipid profiles were classified
as normal or abnormal results.
We collected polyp data from colonoscopy reports.
Advanced colorectal neoplasms were defined as follows:
1) CRC; 2) adenoma with a diameter of ≥10 mm; 3)
tubular adenoma with high-grade dysplasia; and 4) tubu-
lovillous or villous adenoma. When two or more
adenoma were detected, the most advanced lesion was
analyzed based on the largest diameter or advanced hist-
ology. All polyps were evaluated histologically by gastro-
enterology pathologists.
Statistical analysis
Continuous variables were presented as mean ± standard
deviation, and categorical variables were expressed as
percentages. Continuous variables were compared using
Student t-test, whereas categorical variables were com-
pared using chi-square or Fisher exact tests. For predic-
tion model development, differences between variables
were compared in the training set. Before univariate ana-
lysis, continuous variables were converted to categorical
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variables. Variables with a P-value <0.1 in univariate ana-
lysis were included in subsequent multivariate regression
analysis in order to select variables to be implemented in
the final model. Backward elimination (i.e., removing the
covariate with the largest P value, one at a time) was
performed until we developed a final model with statisti-
cally significant covariates. We established a risk score
model by excluding less significant variables in a risk
assessment. We intentionally only used categorized vari-
ables that captured easy but relevant and validated infor-
mation in the prediction model to develop an easy to
use screening score. We used a weighted scoring system
by rounding down odds ratios (ORs) to the nearest inte-
ger in the final model. For example, an OR of 1.96 was
rounded to 1 and an OR of 2.26 was rounded to 2. Based
on this statistical analysis, we developed a formula for
predicting asymptomatic subjects aged 40–49 years with
advanced neoplasm, and these subjects may be primary
candidates for screening colonoscopy. To validate the
model, we assessed the diagnostic accuracy of the model
in the validation set. The sensitivity, specificity, positive
predictive value (PPV), and negative predictive value
(NPV) were calculated using the computed area under
receiver operating characteristic curve (AUROC). There-
after, we validated the diagnostic value of the scoring
model. P < 0.05 was considered to indicate statistical
significance. All analyses were performed using SPSS
software (version 20.0; SPSS Inc.) and MedCalc software
(version 11.1; Mariakerke) for the receiver operating
characteristic analysis.
Results
Baseline characteristics of the total subjects
Among 2781 subjects, mean age was 44.8 ± 2.8 years, and
58.7% (1633/2781) were men. Helicobacter serology posi-
tivity was observed in 1623 (58.4%) patients. Regarding
the prevalence of colorectal neoplasm, advanced neoplasm
was detected in 70 (2.5%) of patients, whereas any type of
colorectal neoplasm was found in 561 (20.2) of patients.
Baseline characteristics of 2781 patients in the training
and validation sets are summarized in Table 1. There was
no statistically significant difference in patient characteris-
tics between the training and validation sets.
Clinicopathological characteristic of the colorectal
neoplasm
Details of the clinicopathological findings of neoplasm
are summarized in Table 2. Among 561 neoplasms,
64 (11.4%) were larger than 10 mm, 537 (95.7%) had
a low-grade tubular adenoma, and 24 (4.3%) had ad-
vanced neoplasm, including 2 patients (0.4%) with
cancer.
Factors associated with advanced colorectal neoplasm in
the development dataset
Univariate analysis showed that male sex (P ≤ 0.001),
the obese group (P = 0.016), positive serology of H.
pylori (P = 0.009), low HDL level (P ≤ 0.001), and high
triglyceride level (P ≤ 0.001) were significantly associated
with the presence of advanced neoplasm. Moreover, the
older age group (45–49 years) was marginally associated
with the presence of advanced neoplasm (P = 0.053). De-
tails of the statistical analysis are summarized in Table 3.
In subsequent multivariate analysis, the older age
group (OR 1.967, 95% CI 1.191–3.749, P = 0.040),
male sex (OR 2.763, 95% CI 1.032–6.409, P = 0.018),
positive serology of H. pylori (OR 2.262, 95% CI
1.108–4.621, P = 0.025), low HDL level (OR 2.219,
95% CI 1.073–4.308, P = 0.031), and high triglyceride
level (OR 1.967, 95% CI 1.143–4.252, P = 0.018) were
identified as independent factors for advanced neo-
plasm. BMI (body mass index) was not significant in
multivariable analysis. Details of these values are
depicted in Table 4.
Table 1 Clinical characteristics of subjects aged 40–49 years
Advanced neoplasm Total subjects (n = 2,781)
Sex
Male 1,633 (58.7)
Female 1,148 (41.3)
Age 44.8 ± 2.8
Age group
40–44 1,259 (45.3)
45–49 1,522 (54.7)
Blood pressure (mmHg)
Systolic blood pressure 120.9 ± 13.9
Diastolic blood pressure 76.3 ± 9.6
Body mass index (kg/m2) 23.4 ± 3.0
Anti-H. pylori IgG (serum)
Positive 1,623 (58.4)
Negative 1,158 (41.6)
Total cholesterol 198.3 ± 34.1
Triglyceride 124.3 ± 81.5
LDL-cholesterol 124.0 ± 31.0
HDL-cholesterol
Men 48.4 ± 10.4
Women 58.6 ± 13.0
Advanced neoplasm 70 (2.5)
Overall neoplasm 561 (20.2)
LDL low-density lipoprotein, HDL high-density lipoprotein, H. pylori,
Helicobacter pylori
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Development of a simple scoring model for predicting
advanced neoplasm
A simple scoring model was constructed based on five
independently significant variables in multivariate ana-
lysis by using rounded down ORs of each variable
(Table 4). The final model is as follows:
A simple scoring model for advanced colorectal
neoplasm = Age [0: 40–44, 1: 45–49 years] × 1 + Sex [0:
female, 1: male] × 2 + Serology of H. pylori [0: negative, 1:
positive] × 2 +High triglyceride level [0: normal range, 1:
high] × 2 + Low HDL level [0: normal range, 1: low] × 2
The range of the total score for this risk model was 0–
9. This model yielded an AUROC of 0.74 for predicting
advanced neoplasm in the development set (Fig. 1a).
Validation of the scoring model in the validation set
We investigated the predicted value of different total
score cut points in the validation sets (Table 5). A cutoff
point of 4 was selected because it results in the highest
value for the AUROC to indicate an individual at high
risk for advanced neoplasm. In the validation set, this
cutoff point designated 43.1% of subjects at high risk
for advanced colorectal neoplasm, and yielded a sensi-
tivity of 79.2%, specificity of 57.8%, PPV of 4.7%, and
NPV of 99.1% with an AUROC of 0.72 (Fig. 1b). The
prevalence of advanced neoplasm gradually increased
as the total risk score increased, and these findings
are depicted in Fig. 2.
Discussion
To the best of our knowledge, our study is the first study
to propose a prediction model for advanced neoplasm in
the 40–49-year-old population. In the 40–49-year-old
group, an increased risk of advanced neoplasm was asso-
ciated with those aged ≥45 years, male sex, positive
serology of H. pylori, and high triglyceride and low HDL
levels. We developed a simple scoring model for
Table 2 Overall colorectal neoplasm in subjects aged 40–49
years
N = 561 %
Number
One 312 55.7
Two 152 27.1
Three or more 96 17.2
Size (mm)*
< 10 496 88.6
≥ 10 64 11.4
Histology*
Low-grade tubular adenoma 537 95.7
High-grade tubular, villous adenoma 22 3.9
Adenocarcinoma 2 0.4
Shape*
Sessile 384 66.9
Semipedunculated 158 28.3
Pedunculated 27 4.8
Location*
Ascending colon 124 22.3
Transverse colon 131 23.4
Descending colon 80 14.3
Rectosigmoid 225 40.0
*Results are summarized according to the most advanced lesion
Table 3 Comparison of variables based on the presence of
advanced neoplasm in the training set
Advanced neoplasm Development set (n = 1,844) P-value
No (n = 1,798) Yes (n = 46)
Sex <0.001
Male 1,044 (96.4) 39 (3.6)
Female 754 (99.1) 7 (0.9)
Age group 0.053
40–44 805 (98.3) 14 (1.7)
45–49 993 (96.9) 32 (3.1)
Blood pressure (mmHg) 0.151
Normal 809 (98.2) 15 (1.8)
Pre-HTN 741 (97.2) 21 (2.8)
HTN 248 (96.1) 10 (3.9)
BMI (kg/m2) 0.016
< 23.0 845 (98.6) 12 (1.4)
< 25.0 458 (96.8) 15 (3.2)
25.0 495 (96.3) 19 (3.7)
Anti-H. pylori IgG 0.009
Positive 1,062 (96.7) 36 (3.3)
Negative 736 (98.7) 10 (1.3)
Total cholesterol 0.755
Normal 1,529 (97.8) 40 (2.2)
Elevation (≥240 mg/dL) 222 (97.5) 5 (2.5)
LDL-c 0.237
Normal 140 (100) 0
Elevation (≥100 mg/dL) 998 (99.0) 10 (1.0)
HDL-c (<40 mg/dL) <0.001
Normal 1,554 (98.1) 30 (1.9)
Low (<40 mg/dL) 244 (93.8) 16 (6.2)
Triglyceride <0.001
Normal 1,588 (98.0) 32 (2.0)
Elevation (≥200 mg/dL) 210 (93.8) 14 (6.3)
HTN hypertension, BMI body mass index, LDL-c low-density lipoprotein, HDL-c
high-density lipoprotein, H. pylori, Helicobacter pylori
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predicting advanced colorectal neoplasm (range 0–9),
and a cutoff point of ≥4 in this model yielded a sensitiv-
ity of 78% and specificity of 56% (AUROC = 0.74) (data
not shown). Comparable results were obtained in the
validation datasets (sensitivity 79%, specificity 58%, and
AUROC = 0.72).
It has been reported that the prevalence of advanced
colorectal neoplasm in individuals aged 40–49 years is
1.3–3.5% [10, 14–17]. Similar to these results, our study
showed a 2.5% prevalence for advanced neoplasm in an
asymptomatic population. Currently, advanced adenoma
is regarded as the most feasible target for CRC screening
[2, 6, 7]. Based on our prediction model, the prevalence
of advanced neoplasm gradually increased as the risk
score increased. This finding suggests that our predic-
tion model can be a reliable tool for identifying target
subjects for CRC screening among persons aged 40–49
years. Our prediction model produced moderate accur-
acy for predicting advanced neoplasm, producing an
AUROC value of 0.72 in the validation cohort.
Regarding age-related risk stratification, our study
showed that the risk for advanced neoplasm was
approximately two times higher in the 45–49 age
group than in the 40–44 age group. This finding suggests
that further subgroup classification can be helpful in iden-
tifying the population at risk within the 40–49 age group,
and it was eventually incorporated into our prediction
model. Similar to our results, Hong et al. [10] also re-
ported that the 45–49 age group had a high adjusted OR
of 1.68 compared to the 40–44 age group for detecting
advanced neoplasm.
Among lipid profile indices, we found that hypertri-
glyceridemia and low HLD-c were independently associ-
ated with advanced neoplasm. In accordance with our
findings, a previous study showed that higher levels of
serum triglyceride were significantly associated with an
increasing prevalence of both non-advanced and ad-
vanced colorectal adenoma in a population aged 40–79
years [18]. Concerning the association between hypertri-
glyceridemia and advanced neoplasm, although the exact
mechanism is currently unclear, several mechanisms
have been suggested. First, hyperinsulinemia and insulin
resistance is affected by apoptosis, thereby a lower rate of
apoptosis in normal colonic mucosa is associated with the
carcinogenesis process, and they may develop into colo-
rectal adenoma, or even cancer [19–21]. Second, hypertri-
glyceridemia can also increase proinflammatory cytokine
levels, and damage deoxyribonucleic acid. These also
affect carcinogenesis through abnormal growth, apoptosis,
and the proliferation of colorectal cells [22–24].
Meanwhile, similar to our results of association be-
tween a low HDL-c level and the risk of advanced neo-
plasm, trends for an increased prevalence of advanced
adenoma with decreasing levels of HDL cholesterol was
also found in previously reported data [18]. Other stud-
ies have also shown that a reduction in HDL cholesterol
levels slightly increases the risk of adenomatous colon
polyps, and consequently colon cancer [25, 26]. Al-
though the underlying mechanism for the relationship
Table 4 Multivariate regression analysis in the development set
Odds ratio
(95% CI)
P-value Score
assigned
Older age (45–49 years) 1.967 (1.191–0.040) 0.040 1
Male sex 2.763 (1.032–0.018) 0.018 2
Positive serology of H. pylori 2.262 (1.108–0.025) 0.025 2
High triglyceride level 2.219 (1.073–0.031) 0.031 2
Low HDL-c 2.136 (1.143–4.252) 0.018 2
CI confidence interval, H. pylori, Helicobacter pylori, HDL-c high-density
lipoprotein cholesterol
A simple scoring model for advanced colorectal neoplasm = Age [0: 40–44, 1:
45–49 years] × 1 + Sex [0: female, 1: male] × 2 + Serology of H. pylori [0:
negative, 1: positive] × 2 + Triglyceride level [0: normal range, 1: high] × 2 +
High-density lipoprotein level [0: normal range, 1: low] × 2
Fig. 1 Area under the receiver operating characteristic (AUROC) curve of the simple scoring model for advanced neoplasm in subjects aged 40–
49 years. An AUROC of 0.74 (95% confidence interval [CI] 0.717–0.757) in development set (a) and an AUROC of 0.72 (95% CI 0.0695–0.753) in the
validation set (b)
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between a low HLD level and the risk of advanced neo-
plasm is still elusive, a low HDL level may result from
interactions with triglyceride and HDL cholesterol, and
the aforementioned possible molecular mechanism asso-
ciated with hypertriglyceridemia and colonic adenoma
may also be involved in these processes. Further exten-
sive molecular biological studies are needed to clarify
the association between dyslipidemia and the risk of
colonic neoplasm.
An association between colorectal neoplasm and H.
pylori infection has been steadily suggested, and meta-
analysis data also demonstrated that H. pylori infection
increase the risk of colorectal neoplasm by 1.4–1.6 times
[27]. In addition, a recent large cross-sectional study
showed that the OR of the group with H. pylori gastritis
is about 1.24–2.35 [28]. In accordance with these obser-
vations, our study also showed that patients with H.
pylori infection are 2.26 times more likely to have ad-
vanced neoplasm compared to patients without H. pylori
infection in subjects aged 40–49 years. Although the re-
lationship between H. pylori infection and increased risk
of colorectal adenoma is unclear, several pathogenic
mechanisms have been suggested. Increased gastrin in-
duced by H. pylori infection may contribute to carcino-
genesis by cell proliferation in the colon mucosa, and H.
pylori itself can act on the colorectal epithelium through
inflammatory responses and affect polyp growth or pro-
mote mucosal dysplasia [29–31].
There are several advantages to our study. First, our
prediction model was developed based on a large study
population that included 1844 and 937 asymptomatic
subjects in the training and validation cohort, respect-
ively. Second, our model consisted of basic demographic
factors and readily available serologic indices. Moreover,
the final score of our model can be calculated in daily
practice; thus, it has potential for high clinical utility in
selective screening colonoscopy among the 40–49-year-
old population. Lastly, our model allows for the adjust-
ment of a cutoff value for subgroup targeting based on
population characteristics and endoscopic resources.
Several limitations of our study should be mentioned.
First, this study was performed in a health promotion cen-
ter of a single university hospital in Korea. Therefore,
generalizability of our results to the general population and
other ethnicities is uncertain. Second, our study did not in-
clude lifestyle factors such as drinking, smoking, physical
activity, and medication history. It has been reported that
these lifestyle factors and some drugs are associated with
the development of colorectal neoplasm [32–34]. Never-
theless, previous data have shown that some lifestyle fac-
tors, including smoking, alcohol, and medication, use were
not significant predictors of advanced neoplasm in average
risk screenees aged 40–49 years [10]. Hypertriglyceridemia
is associated with alcohol consumption and a degree of
smoking. Moreover, low HDL levels are related with a
smoking habit, and its value in serum can be increased by
regular exercise [35–38]. These observations imply that
lipid indices can partly reflect lifestyle characteristics of
each single person, and these lipid indices are incorporated
in our prediction model. Finally, the retrospective nature of
this study poses some limitations. However, our data were
gathered prospectively, and our model largely consisted of
objective results of serology, which were measured on the
same day of colonoscopy. Thus, the influence of this limi-
tation seems to be minimal. Further prospective studies in-
corporating diverse demographic, clinical, and serological
parameters should be conducted.
Conclusions
In conclusion, older age (45–49 years), male sex, positive
serology of H. pylori, and high triglyceride and low HDL
Table 5 Performance of the simple scoring model in the
validation datasets (n = 937)
Score High risk (%) Sensitivity Specificity PPV NPV AUROC
≥0 100 100 0 2.8 0 0.50
≥1 90.2 100 10.1 2.8 100 0.55
≥2 81.1 95.8 19.3 3.0 99.4 0.58
≥3 64.2 87.5 36.4 3.5 99.1 0.62
≥4 43.1 79.2 57.8 4.7 99.1 0.72
≥5 30.3 62.5 70.5 5.3 98.6 0.68
≥6 13.6 37.5 87.1 7.1 98.1 0.62
≥7 8.0 25.0 92.4 8.0 97.9 0.59
≥8 3.4 8.3 96.7 6.2 97.6 0.53
≥9 1.5 4.2 98.6 7.1 97.5 0.51
PPV positive predictive value, NPV negative predictive value, AUROC area
under the receiver operating characteristic curve
Fig. 2 Estimated prevalence of advanced neoplasm according to
the risk score in the validation set. The proportion of subjects with
scores of 0–1, 2–3, 4–5, 6–7, and 8–9 correspond to 0.6, 1.5, 3.0, 6.0,
and 13.0%, respectively. A cutoff point of ≥4 (sensitivity 79%,
specificity 58%) indicates that 43% of subjects are at high risk for
advanced colorectal neoplasm
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levels were identified as independent risk factors for ad-
vanced colorectal neoplasm. A simple scoring model
that consists of five parameters may be useful for select-
ing patients who benefit from screening colonoscopy in
asymptomatic persons aged 40–49 year. We hope that
researchers will evaluate the performance of our predic-
tion model in an independent population to confirm and
validate our results.
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